The
concept of targeted protein degradation presents revolutionary drug development
opportunities and is anticipated to bring about a paradigm shift in modern
healthcare. The first targeted protein degrader, called proteolysis targeting
chimera (PROTAC), was developed about a decade ago.

Presently, a variety of
other such chemical entities and molecular glues are under investigation. In
fact, certain pipeline candidates are already in the mid to late-phase trials
and are anticipated to soon enter the market.

The
USD 3.6 billion (by 2030) financial opportunity within the Target Protein Degradation Market has been analyzed across the following
segments:

Type
of payment of licensing agreements

·       
Upfront payments

·       
Milestone payments

Type
of protein degrader

·       
Degronimids

·       
PROTACs

·       
SARDs / SERDs

·       
Specific BET and DUB inhibitors

·       
Other protein degraders

Therapeutic
area

·       
Neurodegenerative disorders

·       
Oncological disorders

·       
Other therapeutic areas

Route
of administration 

·       
Oral

·       
Intravenous

·       
Other routes

Key
geographical region

·       
North America

·       
Europe

·       
Asia-Pacific

The
Targeted Protein Degradation Market: Focus on Therapeutics and Technology
Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic
Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic
Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors),
2020-2030 report features the following companies, which we identified to be
key players in this domain:

Get
detailed Analysis:

https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html